Johnson & Johnson (NYSE:JNJ) elects Alex Gorsky as chairman of the company

  on Dec 10,2012 Posted in Business News ,Finance
 
Share |
We're on   

Johnson & Johnson (NYSE:JNJ) recently declared Alex Gorsky as chairman of its BODs.

The company appointed Mr. Gorsky as CEO in start of the year 2012. He will take his position as BOD’s chairman along with other leadership responsibilities on 28, December.

Mr. Gorsky will succeed Bill Weldon who will retire in the first quarter of the next year.

Mr. Gorsky stated in a press release that he was honored to replace Bill Weldon as CEO. Bills served JNJ for a period of 41years and will leave him well-positioned to continue to serve the world’s most common diseases and unmet needs in health care, he said.

On 6th December, the company revealed that its Janssen Biotech and Janssen Biologics subsidiaries have submitted applications in the U.S. and Europe to get a green signal for the use of their Stelara psoriasis drug.

Johnson & Johnson (NYSE:JNJ) hit 12.39% as their profit margin for the last twelve months and had an operating margin of 16.68%. Evaluating management effectiveness, return on equity was maintained at 13.58% in last twelve months. Return on assets for Intel was 7.08%. In the previous 52 weeks the price has traded between $61.71 – $72.74. The last session’s volume of 10.00 million shares competed with the average daily trading volume of 10.15 million shares.

Within the industry, Pfizer Inc. (NYSE:PFE) had a 15.69% profit margin in the last twelve months and an operating margin at 20.12%. Return on equity for this company was 11.05% in the last twelve months. Return on assets was 5.03%. In the last year the stock has moved within a range of $20.12 – $26.09. The last session’s volume of 30.75 million shares competed with the average daily trading volume of 32.04 million shares.

Abbott Laboratories (NYSE:ABT) recorded a profit margin of 16.56% for the prior 12 months and an operating margin at 19.67%. Return on equity for this stock was 25.29% while return on assets was 10.62%.

Within the industry, Merck & Co., Inc. (NYSE:MRK) had a 14.41% profit margin in the last twelve months and an operating margin at 18.79%. Return on equity for this company was 12.21% in the last twelve months. Return on assets was 6.48%.

 

 

 

 



 

Leave a Reply